Schmid Andreas, Pankuweit Sabine, Vlacil Ann-Kathrin, Koch Sören, Berge Benedikt, Gajawada Praveen, Richter Manfred, Troidl Kerstin, Schieffer Bernhard, Schäffler Andreas, Grote Karsten
Department of Internal Medicine III, Giessen University Hospital, Giessen, Germany.
Cardiology and Angiology, Philipps-University Marburg, Marburg, Germany.
J Mol Med (Berl). 2024 May;102(5):667-677. doi: 10.1007/s00109-024-02426-8. Epub 2024 Mar 4.
C1q/TNF-related protein 3 (CTRP3) represents an adipokine with various metabolic and immune-regulatory functions. While circulating CTRP3 has been proposed as a potential biomarker for cardiovascular disease (CVD), current data on CTRP3 regarding coronary artery disease (CAD) remains partially contradictory. This study aimed to investigate CTRP3 levels in chronic and acute settings such as chronic coronary syndrome (CCS) and acute coronary syndrome (ACS). A total of 206 patients were classified into three groups: CCS (n = 64), ACS having a first acute event (ACS-1, n = 75), and ACS having a recurrent acute event (ACS-2, n = 67). The control group consisted of 49 healthy individuals. ELISA measurement in peripheral blood revealed decreased CTRP3 levels in all patient groups (p < 0.001) without significant differences between the groups. This effect was exclusively observed in male patients. Females generally exhibited significantly higher CTRP3 plasma levels than males. ROC curve analysis in male patients revealed a valuable predictive potency of plasma CTRP3 in order to identify CAD patients, with a proposed cut-off value of 51.25 ng/mL. The sensitivity and specificity of prediction by CTRP3 were congruent for the subgroups of CCS, ACS-1, and ACS-2 patients. Regulation of circulating CTRP3 levels in murine models of cardiovascular pathophysiology was found to be partly opposite to the clinical findings, with male mice exhibiting higher circulating CTRP3 levels than females. We conclude that circulating CTRP3 levels are decreased in both male CCS and ACS patients. Therefore, CTRP3 might be useful as a biomarker for CAD but not for distinguishing an acute from a chronic setting. KEY MESSAGES: CTRP3 levels were found to be decreased in both male CCS and ACS patients compared to healthy controls. Plasma CTRP3 has a valuable predictive potency in order to identify CAD patients among men and is therefore proposed as a biomarker for CAD but not for distinguishing between acute and chronic settings. Regulation of circulating CTRP3 levels in murine models of cardiovascular pathophysiology was found to be partly opposite to the clinical findings in men.
C1q/TNF相关蛋白3(CTRP3)是一种具有多种代谢和免疫调节功能的脂肪因子。虽然循环CTRP3已被提议作为心血管疾病(CVD)的潜在生物标志物,但目前关于冠状动脉疾病(CAD)的CTRP3数据仍存在部分矛盾。本研究旨在调查慢性和急性情况下,如慢性冠状动脉综合征(CCS)和急性冠状动脉综合征(ACS)中CTRP3的水平。总共206例患者被分为三组:CCS(n = 64)、首次发生急性事件的ACS(ACS-1,n = 75)和复发急性事件的ACS(ACS-2,n = 67)。对照组由49名健康个体组成。外周血ELISA检测显示,所有患者组的CTRP3水平均降低(p < 0.001),但各组之间无显著差异。这种效应仅在男性患者中观察到。女性的CTRP3血浆水平通常显著高于男性。男性患者的ROC曲线分析显示,血浆CTRP3在识别CAD患者方面具有有价值的预测效力,建议的截断值为51.25 ng/mL。CTRP3预测的敏感性和特异性在CCS、ACS-1和ACS-患者亚组中是一致的。在心血管病理生理学小鼠模型中,循环CTRP3水平的调节与临床发现部分相反,雄性小鼠的循环CTRP3水平高于雌性。我们得出结论,男性CCS和ACS患者的循环CTRP3水平均降低。因此,CTRP3可能作为CAD的生物标志物有用,但不能用于区分急性和慢性情况。关键信息:与健康对照相比,男性CCS和ACS患者的CTRP3水平均降低。血浆CTRP3在识别男性CAD患者方面具有有价值的预测效力,因此被提议作为CAD的生物标志物,但不能用于区分急性和慢性情况。在心血管病理生理学小鼠模型中,循环CTRP3水平的调节与男性的临床发现部分相反。